泽夫拉治疗

最新新闻

• Guggenheim Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $23
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• 评级变动
  A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $29
  \u5e02\u573a\u8d44\u8baf · 2026/6/10
• 评级变动
  Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $34
  \u5e02\u573a\u8d44\u8baf · 2026/6/9
• 评级变动
  A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $21 to $28
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Cuts Target Price to $24
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• William Blair Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/5/9
• 公司公告
  KemPharm: KemPharm, Inc. - Name/Symbol Change Option Symbol: KMPH New Symbol: ZVRA
  OCC · 2023/2/28
• 评级变动
  CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $27
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $24 to $28
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/25
• Zevra Therapeutics (ZVRA) Receives a Buy From H.C. Wainwright
  TipRanks · 2026/9/22

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。